Disease/Infection News

RSS

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

Bristol-Myers Squibb Company and the ADAP Crisis Task Force today announced an enhanced agreement to support the efforts of AIDS Drug Assistance Programs to provide antiretroviral medicines to people living with HIV and AIDS. Building on an agreement signed in March of 2010, today's announcement marks a multi-year enhancement to assist ADAPs in meeting the challenges of increasing patient case loads and strained government funding.

12 Aug 2010

HIV patients want docs to pay attention to other health conditions exacerbated by HIV

HIV/AIDS patients need their doctors to pay more attention to their other health conditions that can be exacerbated by HIV or its treatments, especially now that people are living longer with HIV. That is according to a international study of 2,000 patients that two Chicago-area health providers were instrumental in carrying out.

12 Aug 2010

Elsevier launches Malaria Nexus resource to benefit malaria researchers worldwide

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, today announced the launch of Malaria Nexus, Elsevier's Global Malaria Resource. Malaria Nexus highlights the latest published research in Malaria, utilizing Elsevier's leading journals in Parasitology, Entomology and Tropical Medicine, including The Lancet-, The Lancet Infectious Diseases, Transactions of the Royal Society of Tropical Medicine and Hygiene, and International Journal for Parasitology.

12 Aug 2010

Hospital staph infection rate drops as national prevention effort steps up

The rate of drug-resistant staph hospital-acquired infections has dropped as the U.S. has stepped up prevention efforts to fight the deadly condition, The Associated Press reports. "The decline was seen in a federal study of methicillin-resistant staph, or MRSA. The bug often causes only a boil or skin infection. But researchers in the study focused on invasive cases that can become deadly, invading the bloodstream, flesh, lungs and bones. Researchers found that in nine metro areas, cases of MRSA (MUR'-suh) fell about 16 percent between 2005 and 2008.

12 Aug 2010

Human Immune Phenotyping Centers to receive NIAID grants for research

A new nationwide research initiative has been launched to define changes in the human immune system, using human and not animal studies, in response to infection or to vaccination. Six U. S.-based Human Immune Phenotyping Centers will receive a total of $100 million over five years to conduct this research.Funding for the centers is provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Support for the first year of this initiative will come from the American Recovery and Reinvestment Act.

12 Aug 2010

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

AdvanDx today announced the launch of its CE-IVD marked GNR Traffic Light™ PNA FISH® test in Europe. GNR Traffic Light PNA FISH is the first-ever test capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa directly from positive blood cultures in less than 90 minutes.

12 Aug 2010

Scientific research on effects of oil-eating bacteria in Gulf of Mexico waters

The environmental impact of millions of gallons of oil still in the Gulf of Mexico from the Deepwater Horizon incident may depend on microscopic helpers: Bacteria that consume oil and other hydrocarbons and could break down the spilled crude, making it disappear. That's the topic of an article in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

12 Aug 2010

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.

12 Aug 2010

Advaxis, Vibalogics to develop storage-stable formulation for live Listeria vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company and Vibalogics GmbH, a German biologics manufacturing company, have agreed to co-develop a room temperature stable, processing technology for live vaccines originally engineered for Advaxis.

12 Aug 2010

Oral sex becomes common activity among young women: Study

University of Alberta researcher Brea Malacad says results from a study on oral sex indicate there is little doubt that oral sex is becoming a more common activity for young women. Study results show the act has become a fundamental part of what Malacad calls the "sexual revolution of the 21st century". And she concludes that researchers, sex educators and marketers of safer-sex paraphernalia need to catch up with the trend.

12 Aug 2010

AHF led sustained advocacy campaign leads to BMS's offer of discounts in AIDS drug pricing

Following ongoing advocacy campaigns spearheaded by AIDS Healthcare Foundation (AHF) that targeted several of the largest AIDS drug companies over their pricing and rebate policies for the nation's AIDS Drug Assistance Programs (ADAPs), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need, that the last remaining major AIDS drug company, Bristol-Myers Squibb (BMS) today announced an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide.

12 Aug 2010

Chimpanzee adenoviruses can be used as vaccine vectors: Research

In recent years, scientists have studied the possibility of using engineered human adenoviruses as vaccines against diseases such as HIV, tuberculosis, and malaria. In this approach, adenoviruses, which commonly cause respiratory-tract infections, are rendered relatively harmless before they are used as vectors to deliver genes from pathogens, which in turn stimulate the body to generate a protective immune response.

12 Aug 2010

Needle-free natural vaccine against malaria: Research

A study published in the journal Science Translational Medicine proposes that preventative treatment with affordable and safe antibiotics in people living in areas with intense malaria transmission has the potential to act as a 'needle-free' natural vaccine against malaria and may likely provide an additional valuable tool for controlling and/or eliminating malaria in resource-poor settings.

12 Aug 2010

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.

11 Aug 2010

Elsevier launches Global Malaria Resource

11 Aug 2010

Study shows health care-associated invasive MRSA infections decrease among patients

An analysis of data from 2005 through 2008 of nine metropolitan areas in the U.S. indicates that health care-associated invasive methicillin-resistant Staphylococcus aureus infections decreased among patients with infections that began in the community or in the hospital, according to a study in the August 11 issue of JAMA.

11 Aug 2010

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.

11 Aug 2010

WHO declares end of H1N1 pandemic

"World Health Organisation Director-General Margaret Chan announced Tuesday the end of the [H1N1] swine flu pandemic, more than a year after it was declared," Agence France-Presse reports. "The world is no longer in phase 6 of influenza pandemic alert. We are now moving into the post-pandemic period," Chan said during a virtual press conference from Hong Kong, according to a WHO press release (8/10).

11 Aug 2010

NIAID launches clinical trials of dengue vaccine

After more than a decade of development, the National Institute of Allergy and Infectious Diseases (NIAID) has started clinical trials to test a vaccine to protect against the dengue virus, a product researchers hope may one day "help prevent a disease to which 2.5 billion people are exposed," CIDRAP News reports (Roos, 8/9).

11 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Disease/Infection News

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

HIV patients want docs to pay attention to other health conditions exacerbated by HIV

Elsevier launches Malaria Nexus resource to benefit malaria researchers worldwide

Hospital staph infection rate drops as national prevention effort steps up

Human Immune Phenotyping Centers to receive NIAID grants for research

AdvanDx announces European launch of CE-IVD marked GNR Traffic Light PNA FISH test

Scientific research on effects of oil-eating bacteria in Gulf of Mexico waters

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Advaxis, Vibalogics to develop storage-stable formulation for live Listeria vaccines

Oral sex becomes common activity among young women: Study

AHF led sustained advocacy campaign leads to BMS's offer of discounts in AIDS drug pricing

Chimpanzee adenoviruses can be used as vaccine vectors: Research

Needle-free natural vaccine against malaria: Research

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

Elsevier launches Global Malaria Resource

Study shows health care-associated invasive MRSA infections decrease among patients

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

WHO declares end of H1N1 pandemic

NIAID launches clinical trials of dengue vaccine

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News